Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection

被引:34
作者
Störmer, E [1 ]
Bauer, S [1 ]
Kirchheiner, J [1 ]
Brockmöller, J [1 ]
Roots, I [1 ]
机构
[1] Humboldt Univ, Univ Med Ctr Charite, Inst Clin Pharmacol, D-10098 Berlin, Germany
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 783卷 / 01期
关键词
celecoxib; hydroxycelecoxib; carboxycelecoxib;
D O I
10.1016/S1570-0232(02)00658-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A new HPLC method for the simultaneous determination of celecoxib, carboxycelecoxib and hydroxycelecoxib in human plasma samples has been developed. Following a solid-phase extraction procedure, the samples were separated by gradient reversed-phase HLPC (C-18) and quantified using UV detection at 254 run. The method was linear over the concentration range 10-500 ng/ml. The intra-assay variability for the three analytes ranged from 4.0 to 12.6% and the inter-assay variability from 4.9 to 14.2%. The achieved limits of quantitation (LOQ) of 10 ng/ml for each analyte allowed the determination of the pharmacokinetic parameters of the analytes after administration of 100 mg celecoxib. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:207 / 212
页数:6
相关论文
共 10 条
[1]   Clinical pharmacokinetics and pharmacodynamics of celecoxib - A selective cyclo-oxygenase-2 inhibitor [J].
Davies, NM ;
McLachlan, AJ ;
Day, RO ;
Williams, KM .
CLINICAL PHARMACOKINETICS, 2000, 38 (03) :225-242
[2]  
Guirguis MS, 2001, J PHARM PHARM SCI, V4, P1
[3]  
Paulson SK, 2000, DRUG METAB DISPOS, V28, P514
[4]  
Paulson SK, 2000, DRUG METAB DISPOS, V28, P308
[5]   Determination of celecoxib in human plasma by normal-phase high-performance liquid chromatography with column switching and ultraviolet absorbance detection [J].
Rose, MJ ;
Woolf, EJ ;
Matuszewski, BK .
JOURNAL OF CHROMATOGRAPHY B, 2000, 738 (02) :377-385
[6]   Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection [J].
Schönberger, F ;
Heinkele, G ;
Mürdter, TE ;
Brenner, S ;
Klotz, U ;
Hofmann, U .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02) :255-260
[7]   A validated LC method for the quantitative determination of celecoxib in pharmaceutical dosage forms and purity evaluation in bulk drugs [J].
Srinivasu, MK ;
Narayana, CL ;
Rao, DS ;
Reddy, GO .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 22 (06) :949-956
[8]  
Tang CY, 2000, J PHARMACOL EXP THER, V293, P453
[9]   In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P4502C9:: correlation with CYP2C9 genotype and in-vivo pharmacokinetics [J].
Tang, CY ;
Shou, MG ;
Rushmore, TH ;
Mei, Q ;
Sandhu, P ;
Woolf, EJ ;
Rose, MJ ;
Gelmann, A ;
Greenberg, HE ;
De Lepeleire, I ;
Van Hecken, A ;
De Schepper, PJ ;
Ebel, DL ;
Schwartz, JI ;
Rodrigues, AD .
PHARMACOGENETICS, 2001, 11 (03) :223-235
[10]   Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry [J].
Werner, U ;
Werner, D ;
Pahl, A ;
Mundkowski, R ;
Gillich, M ;
Brune, K .
BIOMEDICAL CHROMATOGRAPHY, 2002, 16 (01) :56-60